61results about How to "Impede advancement" patented technology

The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention.

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Syringes and methods of using are described which protect the syringe barrel cavity from contaminants. A first syringe is formed with a corrugated sheath or non-corrugated sheath which is positioned internal or external to the syringe barrel cavity. A second syringe is formed with a syringe barrel having a straight segment and a corrugated segment having the forward face of the plunger handle member molded to the rearward terminus of the corrugated segment of the syringe barrel. A third syringe is formed from mating syringe barrel and plunger member walls. The walls of the mating syringe barrel and plunger member are concentric and slide relative to each other while maintaining an enclosure around the plunger shaft. A fourth syringe is formed from inner and outer concentric syringe barrel walls mating with the walls of a plunger member. The mating walls are concentric and slide relative to each other while maintaining an enclosure around the plunger shaft. A fifth syringe is formed with an end cap contaminant shield having an extension wall that is mated with the inner wall surfaces of the syringe barrel cavity, or outer wall surfaces of the syringe barrel. Alternatively, the end cap contaminant shield can be provided with a flat design without the extending wall and is bonded or molded to the rearward end terminus of the syringe barrel. The end cap contaminant shield designs are provided with an opening defining the shape of the cross-section of the plunger shaft.

A method is disclosed for receiving a plurality of play events associated with a sporting event, wherein each play event of the plurality of play events comprises a timestamp; for each of the play events, associating the play event with a sports team of a plurality of sports teams; for each of the play events, associating with the play event a particular icon from among a plurality of different icons based, at least in part, on the sports team that is associated with the play event; causing to display a bar in a graphical user interface of a mobile computing device, wherein the bar represents at least a portion of a time duration of the sporting event; for each of the play events, causing to display the particular icon at a position in the bar, wherein the position is based, at least in part, on the timestamp of the event.

A method is disclosed for receiving a plurality of play events associated with a sporting event, wherein each play event of the plurality of play events comprises a game clock time, a description, and identifies a sports team of a plurality of sports teams; for each play event in the plurality of play events: generating a graphical tile that is associated with the play event; configuring an appearance of the graphical tile based, at least in part, on the description and the sports team of the play event; causing to display a graphical tile list in a graphical user interface of a mobile computing device, wherein the graphical tile list includes one or more of the graphical tiles listed in a chronological order based on the game clock time in the play event associated with each graphical tile.

The present invention relates to methods for identifying compounds that modulate untranslated region-dependent expression of a target gene. The invention particularly relates to using untranslated regions of a target gene or fragments thereof linked to a reporter gene to identify compounds that modulate untranslated region-dependent expression of a target gene. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads.

The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.

A system and method are provided that use a balloon/stent catheter for placing a stent at the ostium of a blood vessel. Included is a barrier member that is attached to the catheter at a location proximal the balloon. In use, the barrier member is reconfigured, prior to insertion of the balloon/stent portion of the catheter through the ostium. With this reconfiguration, a barrier (array) is established that limits advancement of the catheter into the blood vessel to ensure proper placement of the stent at the ostium.

The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof

The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and/or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and/or for a longer period of time and/or more frequently than currently administered or known to one of skill in the art.

A vehicle brake system includes a brake pedal unit coupled to a vehicle brake pedal. The system includes an input piston connected to operate a pedal simulator during a normal braking mode, and coupled to actuate a pair of output pistons during a manual push through mode. The output pistons are operable to generate brake actuating pressure at first and second outputs of the brake pedal unit. A hydraulic pressure source supplies fluid at a controlled boost pressure. A hydraulic control unit is adapted to be hydraulically connected to the brake pedal unit and the hydraulic pressure source. The hydraulic control unit includes a slip control valve arrangement, and a switching base brake valve arrangement for switching the brake system between the normal braking mode wherein boost pressure from the pressure source is supplied to first and second vehicle brakes, and the manual push through mode wherein brake actuating pressure from the brake pedal unit is supplied to the first and second vehicle brakes. The input piston cooperates with a seal mounted in the brake pedal unit to provide for a progressive rate of friction therebetween as the input piston is advanced in the brake pedal unit by the brake pedal.

The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.

The present invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and/or preventing cancer.

The present invention relates to a method for screening and identifying compounds that modulate the activity of one or more components in the tRNA splicing pathway. In particular the invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease and/or tRNA splicing ligase. The invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease and/or animalia tRNA splicing ligase. The invention also provides assays for the identification of compounds that inhibit fungal tRNA splicing endonuclease and/or fungal tRNA splicing ligase. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and/or preventing cancer and/or fungal infections.

The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with bladder cancer as compared with individuals without bladder cancer. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing bladder cancer. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for bladder cancer.